Laura Walker, PA
Medical · Houston, TXNPI 1699015362
Payments from drug & device makers
Across 61 payments — averaging $25.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$203
- Medtronic$177
- Davol Inc.$171
- AstraZeneca$123
- Mayne Pharma Commercial LLC$110
- Myovant Sciences Inc.$102
- plus $642 from 14 others
What the payments were for
- Food & beverage$1,529100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 15 | $203 |
| Medtronic | 2 | $177 |
| Davol Inc. | 2 | $171 |
| AstraZeneca | 1 | $123 |
| Mayne Pharma Commercial LLC | 4 | $110 |
| Myovant Sciences Inc. | 5 | $102 |
| Sumitomo Pharma America, Inc. | 5 | $101 |
| Exeltis, USA Inc. | 5 | $97 |
| Pfizer | 5 | $91 |
| Galderma Laboratories, L.p. | 2 | $79 |
| Collegium Pharmaceutical, Inc. | 2 | $43 |
| Organon | 3 | $41 |
| Exact Sciences | 2 | $34 |
| Avion Pharmaceuticals | 2 | $32 |
| Hologic Sales And Service, LLC | 1 | $26 |
| Invivyd Inc | 1 | $24 |
| Lupin Inc. | 1 | $22 |
| Coopersurgical, Inc. | 1 | $19 |
| Amgen | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaSeal$154
- SAPHNELO$123
- ARISTA AH FLEXITIP$105
How this compares
$1,529 in reported general payments places this provider in the 60th percentile of 1,490 medical providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol (Once Weekly)Estradiol | 14 | $1,260 |
| Ondansetron OdtOndansetron | 32 | $348 |
Paid to pharmacies, not to this prescriber.
Other medical in Houston
- Olga RodziyenskaHouston$65K
- Kathleen HoganHouston$26K
- Omni McCluneyHouston$18K
- Carl MayberryHouston$18K
- Carley BuddenbaumHouston$16K
- Jose de la CerdaSan Antonio$1.1M
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.